| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9258381 | Seminars in Hematology | 2005 | 4 Pages |
Abstract
Hemolytic transfusion reactions (HTR) are systemic reactions provoked by immunologic red blood cell (RBC) incompatibility. Clinical and experimental observations of such reactions indicate that they proceed through phases of humoral immune reaction, activation of phagocytes, productions of cytokine mediators, and wide-ranging cellular responses. HTR have many features in common with the systemic inflammatory response syndrome (SIRS). Knowledge of the pathophysiologic mechanisms in HTR suggest that newer biological agents that target complement intermediates or proinflammatory cytokines may be effective agents in the treatment of severe HTRs.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Robertson D. Davenport,